Roles of the protein tyrosine phosphatase PTPN22 in immunity and autoimmunity

Clinical Immunology

Volumn 149, Issue 3 PB, 2013, Pages 556-565

  Fousteri, Georgia ^a   Liossis, Stamatis Nick C ^b   Battaglia, Manuela ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF PATRAS   (Greece)

Author keywords

Autoimmunity; Autoreactive cells; Genetic predisposition; Immune tolerance; PTPN22; T regulatory cells (Treg)

Indexed keywords

INTERFERON REGULATORY FACTOR 3; INTERFERON REGULATORY FACTOR 7; INTERLEUKIN 12; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; PROTEIN KINASE SYK; PROTEIN KINASE ZAP 70; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3;

ADAPTIVE IMMUNITY; ANTIGEN RECOGNITION; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; BONE MARROW CELL; CD4+ T LYMPHOCYTE; CROHN DISEASE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; GAIN OF FUNCTION MUTATION; GENETIC PREDISPOSITION; GRAVES DISEASE; HASHIMOTO DISEASE; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MACROPHAGE ACTIVATION; MONOCYTE; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PSORIASIS; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; TH17 CELL; VITILIGO;

EID: 84888022394     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2013.10.006     Document Type: Review

References (66)

1. Bottini N., Musumeci L., Alonso A., Rahmouni S., Nika K., Rostamkhani M., MacMurray J., Meloni G., Lucarelli P., Pellecchia M., Eisenbarth G., Comings D., Mustelin T. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat. Genet. 2004, 36:337-338.
2. Ladner M.B., Bottini N., Valdes A.M., Noble J.A. Association of the single nucleotide polymorphism C1858T of the PTPN22 gene with type 1 diabetes. Hum. Immunol. 2005, 66:60-64.
3. Michou L., Lasbleiz S., Rat A.C., Migliorini P., Balsa A., Westhovens R., Barrera P., Alves H., Pierlot C., Glikmans E., Garnier S., Dausset J., Vaz C., Fernandes M., Petit-Teixeira E., Lemaire I., Pascual-Salcedo D., Bombardieri S., Dequeker J., Radstake T.R., Van Riel P., van de Putte L., Lopes-Vaz A., Prum B., Bardin T., Dieude P., Cornelis F. Linkage proof for PTPN22, a rheumatoid arthritis susceptibility gene and a human autoimmunity gene. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:1649-1654.
4. Chung S.A., Criswell L.A. PTPN22: its role in SLE and autoimmunity. Autoimmunity 2007, 40:582-590.
5. Criswell L.A., Pfeiffer K.A., Lum R.F., Gonzales B., Novitzke J., Kern M., Moser K.L., Begovich A.B., Carlton V.E., Li W., Lee A.T., Ortmann W., Behrens T.W., Gregersen P.K. Analysis of families in the multiple autoimmune disease genetics consortium (MADGC) collection: the PTPN22 620W allele associates with multiple autoimmune phenotypes. Am. J. Hum. Genet. 2005, 76:561-571.
6. Begovich A.B., Caillier S.J., Alexander H.C., Penko J.M., Hauser S.L., Barcellos L.F., Oksenberg J.R. The R620W polymorphism of the protein tyrosine phosphatase PTPN22 is not associated with multiple sclerosis. Am. J. Hum. Genet. 2005, 76:184-187.
7. Nistor I., Nair R.P., Stuart P., Hiremagalore R., Thompson R.A., Jenisch S., Weichenthal M., Abecasis G.R., Qin Z.S., Christophers E., Lim H.W., Voorhees J.J., Elder J.T. Protein tyrosine phosphatase gene PTPN22 polymorphism in psoriasis: lack of evidence for association. J. Invest. Dermatol. 2005, 125:395-396.
8. Zoledziewska M., Perra C., Orru V., Moi L., Frongia P., Congia M., Bottini N., Cucca F. Further evidence of a primary, causal association of the PTPN22 620W variant with type 1 diabetes. Diabetes 2008, 57:229-234.
9. Long A., Buckner J.H. Intersection between genetic polymorphisms and immune deviation in type 1 diabetes. Curr. Opin. Endocrinol. Diabetes Obes. 2013, 20:285-291.
10. Smyth D., Cooper J.D., Collins J.E., Heward J.M., Franklyn J.A., Howson J.M., Vella A., Nutland S., Rance H.E., Maier L., Barratt B.J., Guja C., Ionescu-Tirgoviste C., Savage D.A., Dunger D.B., Widmer B., Strachan D.P., Ring S.M., Walker N., Clayton D.G., Twells R.C., Gough S.C., Todd J.A. Replication of an association between the lymphoid tyrosine phosphatase locus (LYP/PTPN22) with type 1 diabetes, and evidence for its role as a general autoimmunity locus. Diabetes 2004, 53:3020-3023.
11. Dultz G., Matheis N., Dittmar M., Rohrig B., Bender K., Kahaly G.J. The protein tyrosine phosphatase non-receptor type 22 C1858T polymorphism is a joint susceptibility locus for immunthyroiditis and autoimmune diabetes. Thyroid 2009, 19:143-148.
12. van Oene M., Wintle R.F., Liu X., Yazdanpanah M., Gu X., Newman B., Kwan A., Johnson B., Owen J., Greer W., Mosher D., Maksymowych W., Keystone E., Rubin L.A., Amos C.I., Siminovitch K.A. Association of the lymphoid tyrosine phosphatase R620W variant with rheumatoid arthritis, but not Crohn's disease, in Canadian populations. Arthritis Rheum. 2005, 52:1993-1998.
13. Totaro M., Tolusso B., Napolioni V., Faustini F., Canestri S., Mannocci A., Gremese E., Bosello S., Alivernini S., Ferraccioli G. PTPN22 1858C>T polymorphism distribution in Europe and association with rheumatoid arthritis: case-control study and meta-analysis. PLoS ONE 2011, 6.
14. Wu H., Cantor R.M., Graham D.S., Lingren C.M., Farwell L., Jager P.L., Bottini N., Grossman J.M., Wallace D.J., Hahn B.H., Julkunen H., Hebert L.A., Rovin B.H., Birmingham D.J., Rioux J.D., Yu C.Y., Kere J., Vyse T.J., Tsao B.P. Association analysis of the R620W polymorphism of protein tyrosine phosphatase PTPN22 in systemic lupus erythematosus families: increased T allele frequency in systemic lupus erythematosus patients with autoimmune thyroid disease. Arthritis Rheum. 2005, 52:2396-2402.
15. Canton I., Akhtar S., Gavalas N.G., Gawkrodger D.J., Blomhoff A., Watson P.F., Weetman A.P., Kemp E.H. A single-nucleotide polymorphism in the gene encoding lymphoid protein tyrosine phosphatase (PTPN22) confers susceptibility to generalised vitiligo. Genes Immun. 2005, 6:584-587.
16. Velaga M.R., Wilson V., Jennings C.E., Owen C.J., Herington S., Donaldson P.T., Ball S.G., James R.A., Quinton R., Perros P., Pearce S.H. The codon 620 tryptophan allele of the lymphoid tyrosine phosphatase (LYP) gene is a major determinant of Graves' disease. J. Clin. Endocrinol. Metab. 2004, 89:5862-5865.
17. Burn G., Svensson L., Sanchez-Blanco C., Saini M., Cope A. Why is PTPN22 a good candidate susceptibility gene for autoimmune disease?. FEBS Lett. 2011, 585:3689-3698.
18. Shapira Y., Agmon-Levin N., Shoenfeld Y. Geoepidemiology of autoimmune rheumatic diseases. Nat. Rev. Rheumatol. 2010, 6:468-476.
19. Solovieff N., Cotsapas C., Lee P.H., Purcell S.M., Smoller J.W. Pleiotropy in complex traits: challenges and strategies. Nat. Rev. Genet. 2013, 14:483-495.
20. Anaya J.M., Gomez L., Castiblanco J. Is there a common genetic basis for autoimmune diseases?. Clin. Dev. Immunol. 2006, 13:185-195.
21. Cohen S., Dadi H., Shaoul E., Sharfe N., Roifman C.M. Cloning and characterization of a lymphoid-specific, inducible human protein tyrosine phosphatase, Lyp. Blood 1999, 93:2013-2024.
22. Gjorloff-Wingren A., Saxena M., Williams S., Hammi D., Mustelin T. Characterization of TCR-induced receptor-proximal signaling events negatively regulated by the protein tyrosine phosphatase PEP. Eur. J. Immunol. 1999, 29:3845-3854.
23. Hasegawa K. PEST domain-enriched tyrosine phosphatase (PEP) regulation of effector/memory T cells. Science 2004, 303.
24. Delogu L.G., Magrini A., Bergamaschi A., Rosato N., Dawson M.I., Bottini N., Bottini M. Conjugation of antisense oligonucleotides to PEGylated carbon nanotubes enables efficient knockdown of PTPN22 in T lymphocytes. Bioconjug. Chem. 2009, 20:427-431.
25. Tian Z., Gershwin M.E., Zhang C. Regulatory NK cells in autoimmune disease. J. Autoimmun. 2012, 39:206-215.
26. Simoni Y., Diana J., Ghazarian L., Beaudoin L., Lehuen A. Therapeutic manipulation of natural killer (NK) T cells in autoimmunity: are we close to reality?. Clin. Exp. Immunol. 2013, 171:8-19.
27. Douroudis K., Shcherbakova A., Everaus H., Aints A. PTPN22 gene regulates natural killer cell proliferation during in vitro expansion. Tissue Antigens 2010, 76:315-318.
28. Newman K.C., Riley E.M. Whatever turns you on: accessory-cell-dependent activation of NK cells by pathogens. Nat. Rev. Immunol. 2007, 7:279-291.
29. Spalinger M., Lang S., Weber A., Frei P., Fried M., Rogler G., Scharl M. Loss of protein tyrosine phosphatase non-receptor type 22 regulates interferon-γ-induced signaling in human monocytes. Gastroenterology 2013, 144:978-988.
30. Chang H.H., Miaw S.C., Tseng W., Sun Y.W., Liu C.C., Tsao H.W., Ho I.C. ptpn22 modulates macrophage polarization and susceptibility to dextran sulfate sodium-induced colitis. J. Immunol. 2013, 191:2134-2143.
31. Wang Y., Shaked I., Stanford S.M., Zhou W., Curtsinger J.M., Mikulski Z., Shaheen Z.R., Cheng G., Sawatzke K., Campbell A.M., Auger J.L., Bilgic H., Shoyama F.M., Schmeling D.O., Balfour H.H., Hasegawa K., Chan A.C., Corbett J.A., Binstadt B.A., Mescher M.F., Ley K., Bottini N., Peterson E.J. The autoimmunity-associated gene PTPN22 potentiates toll-like receptor-driven, type 1 interferon-dependent immunity. Immunity 2013, 39:111-122.
32. Banchereau J., Pascual V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 2006, 25:383-392.
33. Lichtman E.I., Helfgott S.M., Kriegel M.A. Emerging therapies for systemic lupus erythematosus-focus on targeting interferon-alpha. Clin. Immunol. 2012, 143:210-221.
34. Chen G., Shaw M.H., Kim Y.G., Nunez G. NOD-like receptors: role in innate immunity and inflammatory disease. Annu. Rev. Pathol. 2009, 4:365-398.
35. Spalinger M.R., Lang S., Vavricka S.R., Fried M., Rogler G., Scharl M. Protein tyrosine phosphatase non-receptor type 22 modulates NOD2-induced cytokine release and autophagy. PLoS One 2013, 8:e72384.
36. Zhang J., Zahir N., Jiang Q., Miliotis H., Heyraud S., Meng X., Dong B., Xie G., Qiu F., Hao Z., McCulloch C., Keystone E., Peterson A., Siminovitch K. The autoimmune disease-associated PTPN22 variant promotes calpain-mediated Lyp/Pep degradation associated with lymphocyte and dendritic cell hyperresponsiveness. Nat. Genet. 2011, 43:902-907.
37. Vang T., Liu W.H., Delacroix L., Wu S., Vasile S., Dahl R., Yang L., Musumeci L., Francis D., Landskron J., Tasken K., Tremblay M.L., Lie B.A., Page R., Mustelin T., Rahmouni S., Rickert R.C., Tautz L. LYP inhibits T-cell activation when dissociated from CSK. Nat. Chem. Biol. 2012, 8:437-446.
38. Dai X., James R.G., Habib T., Singh S., Jackson S., Khim S., Moon R.T., Liggitt D., Wolf-Yadlin A., Buckner J.H., Rawlings D.J. A disease-associated PTPN22 variant promotes systemic autoimmunity in murine models. J. Clin. Invest. 2013, 123:2024-2036.
39. Brownlie R.J., Miosge L.A., Vassilakos D., Svensson L.M., Cope A., Zamoyska R. Lack of the phosphatase PTPN22 increases adhesion of murine regulatory T cells to improve their immunosuppressive function. Sci. Signal. 2012, 5.
40. Maine C., Hamilton-Williams E., Cheung J., Stanford S., Bottini N., Wicker L., Sherman L. PTPN22 alters the development of regulatory T cells in the thymus. J. Immunol. 2012, 188:5267-5275.
41. Zheng P., Kissler S. PTPN22 silencing in the NOD model indicates the type 1 diabetes-associated allele is not a loss-of-function variant. Diabetes 2013, 62:896-904.
42. Yeh L.T., Miaw S.C., Lin M.H., Chou F.C., Shieh S.J., Chuang Y.P., Lin S.H., Chang D.M., Sytwu H.K. Different modulation of ptpn22 in effector and regulatory T cells leads to attenuation of autoimmune diabetes in transgenic nonobese diabetic mice. J. Immunol. 2013, 191:594-607.
43. Vang T., Landskron J., Viken M.K., Oberprieler N., Torgersen K.M., Mustelin T., Tasken K., Tautz L., Rickert R.C., Lie B.A. The autoimmune-predisposing variant of lymphoid tyrosine phosphatase favors T helper 1 responses. Hum. Immunol. 2013, 74:574-585.
44. Haluszczak C., Akue A.D., Hamilton S.E., Johnson L.D., Pujanauski L., Teodorovic L., Jameson S.C., Kedl R.M. The antigen-specific CD8+ T cell repertoire in unimmunized mice includes memory phenotype cells bearing markers of homeostatic expansion. J. Exp. Med. 2009, 206:435-448.
45. Curotto de Lafaille M., Lafaille J. Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor?. Immunity 2009, 30:626-635.
46. Zikherman J., Hermiston M., Steiner D., Hasegawa K., Chan A., Weiss A. PTPN22 deficiency cooperates with the CD45 E613R allele to break tolerance on a non-autoimmune background. J. Immunol. 2009, 182.
47. Vang T., Congia M., Macis M.D., Musumeci L., Orru V., Zavattari P., Nika K., Tautz L., Tasken K., Cucca F., Mustelin T., Bottini N. Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nat. Genet. 2005, 37:1317-1319.
48. Rieck M., Arechiga A., Onengut-Gumuscu S., Greenbaum C., Concannon P., Buckner J. Genetic variation in PTPN22 corresponds to altered function of T and B lymphocytes. J. Immunol. 2007, 179:4704-4710.
49. Long S.A., Rieck M., Sanda S., Bollyky J.B., Samuels P.L., Goland R., Ahmann A., Rabinovitch A., Aggarwal S., Phippard D., Turka L.A., Ehlers M.R., Bianchine P.J., Boyle K.D., Adah S.A., Bluestone J.A., Buckner J.H., Greenbaum C.J. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs beta-cell function. Diabetes 2012, 61:2340-2348.
50. Garg G., Tyler J.R., Yang J.H., Cutler A.J., Downes K., Pekalski M., Bell G.L., Nutland S., Peakman M., Todd J.A., Wicker L.S., Tree T.I. Type 1 diabetes-associated IL2RA variation lowers IL-2 signaling and contributes to diminished CD4+CD25+ regulatory T cell function. J. Immunol. 2012, 188:4644-4653.
51. Jailwala P., Waukau J., Glisic S., Jana S., Ehlenbach S., Hessner M., Alemzadeh R., Matsuyama S., Laud P., Wang X., Ghosh S. Apoptosis of CD4+CD25(high) T cells in type 1 diabetes may be partially mediated by IL-2 deprivation. PLoS ONE 2009, 4:e6527.
52. Vassilopoulos D., Kovacs B., Tsokos G.C. TCR/CD3 complex-mediated signal transduction pathway in T cells and T cell lines from patients with systemic lupus erythematosus. J. Immunol. 1995, 155:2269-2281.
53. Enyedy E.J., Nambiar M.P., Liossis S.N., Dennis G., Kammer G.M., Tsokos G.C. Fc epsilon receptor type I gamma chain replaces the deficient T cell receptor zeta chain in T cells of patients with systemic lupus erythematosus. Arthritis Rheum. 2001, 44:1114-1121.
54. Tsokos G.C., Nambiar M.P., Tenbrock K., Juang Y.T. Rewiring the T-cell: signaling defects and novel prospects for the treatment of SLE. Trends Immunol. 2003, 24:259-263.
55. Solomou E.E., Juang Y.T., Gourley M.F., Kammer G.M., Tsokos G.C. Molecular basis of deficient IL-2 production in T cells from patients with systemic lupus erythematosus. J. Immunol. 2001, 166:4216-4222.
56. Vinuesa C.G., Linterman M.A., Goodnow C.C., Randall K.L. T cells and follicular dendritic cells in germinal center B-cell formation and selection. Immunol. Rev. 2010, 237:72-89.
57. Linterman M.A., Liston A., Vinuesa C.G. T-follicular helper cell differentiation and the co-option of this pathway by non-helper cells. Immunol. Rev. 2012, 247:143-159.
58. Craft J.E. Follicular helper T cells in immunity and systemic autoimmunity. Nat. Rev. Rheumatol. 2012, 8:337-347.
59. Liossis S.N., Kovacs B., Dennis G., Kammer G.M., Tsokos G.C. B cells from patients with systemic lupus erythematosus display abnormal antigen receptor-mediated early signal transduction events. J. Clin. Invest. 1996, 98:2549-2557.
60. Liossis S.N., Solomou E.E., Dimopoulos M.A., Panayiotidis P., Mavrikakis M.M., Sfikakis P.P. B-cell kinase lyn deficiency in patients with systemic lupus erythematosus. J. Investig. Med. 2001, 49:157-165.
61. Habib T., Funk A., Rieck M., Brahmandam A., Dai X., Panigrahi A.K., Luning Prak E.T., Meyer-Bahlburg A., Sanda S., Greenbaum C., Rawlings D.J., Buckner J.H. Altered B cell homeostasis is associated with type I diabetes and carriers of the PTPN22 allelic variant. J. Immunol. 2012, 188:487-496.
62. Arechiga A.F., Habib T., He Y., Zhang X., Zhang Z.Y., Funk A., Buckner J.H. Cutting edge: the PTPN22 allelic variant associated with autoimmunity impairs B cell signaling. J. Immunol. 2009, 182:3343-3347.
63. Meffre E. The establishment of early B cell tolerance in humans: lessons from primary immunodeficiency diseases. Ann. N. Y. Acad. Sci. 2011, 1246:1-10.
64. Duty J.A., Szodoray P., Zheng N.Y., Koelsch K.A., Zhang Q., Swiatkowski M., Mathias M., Garman L., Helms C., Nakken B., Smith K., Farris A.D., Wilson P.C. Functional anergy in a subpopulation of naive B cells from healthy humans that express autoreactive immunoglobulin receptors. J. Exp. Med. 2009, 206:139-151.
65. Menard L., Saadoun D., Isnardi I., Ng Y.-S., Meyers G., Massad C., Price C., Abraham C., Motaghedi R., Buckner J., Gregersen P., Meffre E. The PTPN22 allele encoding an R620W variant interferes with the removal of developing autoreactive B cells in humans. J. Clin. Invest. 2011, 121:3635-3644.
66. Barrett J.C., Clayton D.G., Concannon P., Akolkar B., Cooper J.D., Erlich H.A., Julier C., Morahan G., Nerup J., Nierras C., Plagnol V., Pociot F., Schuilenburg H., Smyth D.J., Stevens H., Todd J.A., Walker N.M., Rich S.S. Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat. Genet. 2009, 41:703-707.